Skip to content
Bora Haber
Markets
  • US dollar50.49up 0.05%
  • Euro55.40down 0.11%
  • British pound66.28down 0.33%
  • BIST 10011,131down 3.02%
  • Gold (gram)5,707up 0.05%
  • Gold (ounce)US$3,515unchanged 0.0%
  • BitcoinUS$60,863up 0.87%
BREAKING

Total tumor volume emerges as key predictor of survival in prostate cancer

An international study involving Atatürk University finds that as total tumor volume calculated from PSMA PET images increases, survival time for prostate cancer patients shortens.

Nehir Gökçe

· 2 min read

On a screen, a white patient table moves toward the round opening of a medical device, with a radiation warning symbol on its
Medical imaging equipment, one of the tools used to assess tumor volume in cancer care. Temsili görsel · Fotoğraf: MART PRODUCTION / Pexels

Total tumor volume in the body has proven to be a highly valuable indicator of life expectancy in prostate cancer patients. The international study, with contributions from 6 centers across Europe, Asia, North America, South America, Africa and Australia, plus Türkiye, was published in The Journal of Nuclear Medicine, one of the respected journals in nuclear medicine.

What the study did

Prepared with the work of around 130 researchers, the study evaluated prostate-specific antigen (PSA) blood values and prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging data of 14 thousand people diagnosed with prostate cancer in 2012-2024. Patients were divided into groups by total tumor volume calculated from PSMA PET images, and overall survival probabilities were determined. The analyses were carried out on previously taken PET scans and blood values.

Findings

According to Assoc. Prof. Dr. Adem Maman of Atatürk University, patients' condition had mostly been assessed by looking at blood PSA levels or the brightness of the tumor on PET images. The new study showed that the decisive factor is total tumor volume in the prostate. Total tumor volume can be obtained by measuring individual lesions. As volume grows, average survival time falls; as it shrinks, survival time lengthens.

Maman said that in patients whose total volume is above 16 milliliters, 7-year survival is around 35 percent, while as volume drops this rises to around 85 percent.

Yani tümör hacmi, aslında tedavinin şeklini de değiştirmiş olacak, tümör volümüne göre tedavi seçimi olacak.

Assoc. Prof. Dr. Adem Maman

Bora Haber previously reported: Prof. Dr. Bülent Erbil: Türkiye has a voice in emergency medicine worldwide.

Background

Maman said prostate cancer is the most common cancer in men and the second leading cause of cancer death after lung cancer. Stressing the importance of accurate staging after diagnosis, he explained that PET scanning after a low dose of radioactive substance shows both the cancer in the prostate gland and its points of spread, including bone metastases, clearly.

Saying Atatürk University is proud to take part in a worldwide project with 43 hospitals from 6 continents, Maman added that the study could in future be integrated into a system measurable by artificial intelligence or computer.

Science guides

Take a quiz, vote in a poll

Video news

Comments

Sign in to comment.

More on this topic

See all